A valuable and intuitive diagnostic tool for acute kidney injury in Liver cirrhosis is the fractional excretion of urea and sodium

Abstract

Background: Prerenal and renal acute kidney injury (AKI) phenotypes could develop among patients with decompensated cirrhosis. Their prognosis and outcomes for therapy vary significantly. Each AKI type has a unique treatment approach; thus, it's critical to diagnose and initiate therapy for each immediately. Aim of the study: We aimed to determine if fractional excretion of Urea and Sodium (FEUrea and FENa) may be valuable for distinguishing AKI phenotypes. Methods: An observational study was conducted between May 2022–and May 2022. Enrolled in the trial were 50 cirrhotic patients without AKI and 100 cirrhotic patients with AKI. Every patient had a comprehensive clinical evaluation and history taking. Both groups' fractional excretion of urea and sodium was measured (Trial registration number Trial Register NCT0367563).